{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T04:11:54Z","timestamp":1783656714760,"version":"3.55.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13722-017-0072-2","type":"journal-article","created":{"date-parts":[[2017,2,28]],"date-time":"2017-02-28T14:39:58Z","timestamp":1488292798000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Public sector low threshold office-based buprenorphine treatment: outcomes at year 7"],"prefix":"10.1186","volume":"12","author":[{"given":"Elenore Patterson","family":"Bhatraju","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellie","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babak","family":"Tofighi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"McNeely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danae","family":"DiRocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Flannery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Garment","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Goldfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc N.","family":"Gourevitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,28]]},"reference":[{"key":"72_CR1","volume-title":"Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction","author":"Substance Abuse and Mental Health Service Administration","year":"2004","unstructured":"Substance Abuse and Mental Health Service Administration. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Rockville: Center for Substance Abuse Treatment; 2004."},{"issue":"2","key":"72_CR2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jsat.2004.06.005","volume":"27","author":"DA Fiellin","year":"2004","unstructured":"Fiellin DA, et al. Consensus statement on office-based treatment of opioid dependence using buprenorphine. J Subst Abuse Treat. 2004;27(2):153\u20139.","journal-title":"J Subst Abuse Treat"},{"issue":"5","key":"72_CR3","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/ADM.0000000000000166","volume":"9","author":"K Kampman","year":"2015","unstructured":"Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. J Addict Med. 2015;9(5):358\u201367.","journal-title":"J Addict Med"},{"issue":"6","key":"72_CR4","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s11606-011-1962-8","volume":"27","author":"BR Schackman","year":"2012","unstructured":"Schackman BR, et al. Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care. J Gen Intern Med. 2012;27(6):669\u201376.","journal-title":"J Gen Intern Med"},{"issue":"12","key":"72_CR5","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1001\/jamainternmed.2014.5302","volume":"174","author":"DA Fiellin","year":"2014","unstructured":"Fiellin DA, et al. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial. JAMA Intern Med. 2014;174(12):1947\u201354.","journal-title":"JAMA Intern Med"},{"issue":"1","key":"72_CR6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1370\/afm.1735","volume":"13","author":"RA Rosenblatt","year":"2015","unstructured":"Rosenblatt RA, et al. Geographic and specialty distribution of US physicians trained to treat opioid use disorder. Ann Fam Med. 2015;13(1):23\u20136.","journal-title":"Ann Fam Med"},{"issue":"4","key":"72_CR7","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1001\/jamapsychiatry.2013.4450","volume":"71","author":"SC Sigmon","year":"2014","unstructured":"Sigmon SC. Access to treatment for opioid dependence in rural America: challenges and future directions. JAMA Psychiatry. 2014;71(4):359\u201360.","journal-title":"JAMA Psychiatry"},{"issue":"9","key":"72_CR8","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMp1604223","volume":"375","author":"AR Williams","year":"2016","unstructured":"Williams AR, Bisaga A. From AIDS to opioids\u2014How to combat an epidemic. N Engl J Med. 2016;375(9):813\u20135.","journal-title":"N Engl J Med"},{"issue":"3","key":"72_CR9","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11414-013-9341-3","volume":"40","author":"HB Hansen","year":"2013","unstructured":"Hansen HB, et al. Variation in use of buprenorphine and methadone treatment by racial, ethnic, and income characteristics of residential social areas in New York City. J Behav Health Serv Res. 2013;40(3):367\u201377.","journal-title":"J Behav Health Serv Res"},{"key":"72_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsat.2016.10.005","volume":"74","author":"A Kermack","year":"2017","unstructured":"Kermack A, Flannery M, Tofighi B, McNeely J, Lee JD. Buprenorphine prescribing practice trends and attitudes among New York providers. J Subst Abuse Treat. 2017;74:1\u20136.","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"72_CR11","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s11606-008-0881-9","volume":"24","author":"DT Barry","year":"2009","unstructured":"Barry DT, et al. Integrating buprenorphine treatment into office-based practice: a qualitative study. J Gen Intern Med. 2009;24(2):218\u201325.","journal-title":"J Gen Intern Med"},{"issue":"2","key":"72_CR12","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1370\/afm.1595","volume":"12","author":"E Hutchinson","year":"2014","unstructured":"Hutchinson E, et al. Barriers to primary care physicians prescribing buprenorphine. Ann Fam Med. 2014;12(2):128\u201333.","journal-title":"Ann Fam Med"},{"issue":"4","key":"72_CR13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1300\/J069v25n04_09","volume":"25","author":"W Kissin","year":"2006","unstructured":"Kissin W, et al. Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence. J Addict Dis. 2006;25(4):91\u2013103.","journal-title":"J Addict Dis"},{"issue":"3","key":"72_CR14","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jsat.2008.06.006","volume":"36","author":"J Netherland","year":"2009","unstructured":"Netherland J, et al. Factors affecting willingness to provide buprenorphine treatment. J Subst Abuse Treat. 2009;36(3):244\u201351.","journal-title":"J Subst Abuse Treat"},{"issue":"9","key":"72_CR15","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s11606-008-0686-x","volume":"23","author":"AY Walley","year":"2008","unstructured":"Walley AY, et al. Office-based management of opioid dependence with buprenorphine: clinical practices and barriers. J Gen Intern Med. 2008;23(9):1393\u20138.","journal-title":"J Gen Intern Med"},{"key":"72_CR16","unstructured":"Reckitt Benkiser Pharmaceutical Inc. Full prescribing information, Suboxone sublingual tablets. 2011. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/020733s007s008lbl.pdf ."},{"key":"72_CR17","unstructured":"UnitedHealth Community Plan. Suboxone\/Subutex\/Zubsolv PRIOR AUTHORIZATION REQUEST. 2016. https:\/\/www.uhccommunityplan.com\/content\/dam\/communityplan\/healthcareprofessionals\/pharmacyprogram\/all-Suboxone.pdf ."},{"issue":"5","key":"72_CR18","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1001\/archinternmed.2010.541","volume":"171","author":"DP Alford","year":"2011","unstructured":"Alford DP, et al. Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. Arch Intern Med. 2011;171(5):425\u201331.","journal-title":"Arch Intern Med"},{"issue":"Suppl 1","key":"72_CR19","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1097\/QAI.0b013e318209751e","volume":"56","author":"FL Altice","year":"2011","unstructured":"Altice FL, et al. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine\/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S22\u201332.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"7","key":"72_CR20","first-page":"500","volume":"40","author":"C Cunningham","year":"2008","unstructured":"Cunningham C, et al. Buprenorphine treatment in an urban community health center: what to expect. Fam Med. 2008;40(7):500\u20136.","journal-title":"Fam Med"},{"issue":"2","key":"72_CR21","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1370\/afm.665","volume":"5","author":"IL Mintzer","year":"2007","unstructured":"Mintzer IL, et al. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. Ann Fam Med. 2007;5(2):146\u201350.","journal-title":"Ann Fam Med"},{"issue":"4","key":"72_CR22","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jsat.2009.05.003","volume":"37","author":"JM Soeffing","year":"2009","unstructured":"Soeffing JM, et al. Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year. J Subst Abuse Treat. 2009;37(4):426\u201330.","journal-title":"J Subst Abuse Treat"},{"issue":"3","key":"72_CR23","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1080\/10550887.2012.694603","volume":"31","author":"S Stancliff","year":"2012","unstructured":"Stancliff S, et al. Opioid maintenance treatment as a harm reduction tool for opioid-dependent individuals in New York City: the need to expand access to buprenorphine\/naloxone in marginalized populations. J Addict Dis. 2012;31(3):278\u201387.","journal-title":"J Addict Dis"},{"issue":"1\u20132","key":"72_CR24","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.drugalcdep.2012.12.008","volume":"131","author":"MS Haddad","year":"2013","unstructured":"Haddad MS, Zelenev A, Altice FL. Integrating buprenorphine maintenance therapy into federally qualified health centers: real-world substance abuse treatment outcomes. Drug Alcohol Depend. 2013;131(1\u20132):127\u201335.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"72_CR25","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s11606-008-0866-8","volume":"24","author":"JD Lee","year":"2009","unstructured":"Lee JD, et al. Home buprenorphine\/naloxone induction in primary care. J Gen Intern Med. 2009;24(2):226\u201332.","journal-title":"J Gen Intern Med"},{"issue":"5","key":"72_CR26","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/ADM.0000000000000059","volume":"8","author":"JD Lee","year":"2014","unstructured":"Lee JD, Vocci F, Fiellin DA. Unobserved \u201chome\u201d induction onto buprenorphine. J Addict Med. 2014;8(5):299\u2013308.","journal-title":"J Addict Med"},{"issue":"2","key":"72_CR27","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1080\/10550490701860971","volume":"17","author":"DA Fiellin","year":"2008","unstructured":"Fiellin DA, et al. Long-term treatment with buprenorphine\/naloxone in primary care: results at 2\u20135 years. Am J Addict. 2008;17(2):116\u201320.","journal-title":"Am J Addict"},{"issue":"3","key":"72_CR28","first-page":"189","volume":"1","author":"LR Martin","year":"2005","unstructured":"Martin LR, et al. The challenge of patient adherence. Ther Clin Risk Manag. 2005;1(3):189\u201399.","journal-title":"Ther Clin Risk Manag"},{"issue":"5","key":"72_CR29","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1086\/649933","volume":"50","author":"E Horstmann","year":"2010","unstructured":"Horstmann E, et al. Retaining HIV-infected patients in care: Where are we? Where do we go from here? Clin Infect Dis. 2010;50(5):752\u201361.","journal-title":"Clin Infect Dis"},{"key":"72_CR30","doi-asserted-by":"crossref","unstructured":"McLellan AT, Starrels JL, Tai B, Gordon AJ, Brown R, Ghitza U, Gourevitch M, Stein J, Oros M, Horton T, Lindblad R, McNeely J. Can Substance Use Disorders be Managed Using the Chronic Care Model? Review and Recommendations from a NIDA Consensus Group. Public Health Rev. 2014;35(2). PMID: 26568649. http:\/\/www.journalindex.net\/visit.php?j=6676 .","DOI":"10.1007\/BF03391707"},{"key":"72_CR31","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.drugalcdep.2015.02.030","volume":"150","author":"RD Weiss","year":"2015","unstructured":"Weiss RD, et al. Long-term outcomes from the national drug abuse treatment clinical trials network prescription opioid addiction treatment study. Drug Alcohol Depend. 2015;150:112\u20139.","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"72_CR32","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jsat.2010.12.002","volume":"40","author":"CO Cunningham","year":"2011","unstructured":"Cunningham CO, et al. A comparison of buprenorphine induction strategies: patient-centered home-based inductions versus standard-of-care office-based inductions. J Subst Abuse Treat. 2011;40(4):349\u201356.","journal-title":"J Subst Abuse Treat"},{"issue":"5","key":"72_CR33","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.addbeh.2010.01.001","volume":"35","author":"EW Gunderson","year":"2010","unstructured":"Gunderson EW, et al. Unobserved versus observed office buprenorphine\/naloxone induction: a pilot randomized clinical trial. Addict Behav. 2010;35(5):537\u201340.","journal-title":"Addict Behav"},{"issue":"1","key":"72_CR34","doi-asserted-by":"crossref","first-page":"38","DOI":"10.5694\/j.1326-5377.2003.tb05417.x","volume":"179","author":"AE Gibson","year":"2003","unstructured":"Gibson AE, et al. A comparison of buprenorphine treatment in clinic and primary care settings: a randomised trial. Med J Aust. 2003;179(1):38\u201342.","journal-title":"Med J Aust"},{"issue":"2","key":"72_CR35","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jsat.2009.08.001","volume":"38","author":"NL Sohler","year":"2010","unstructured":"Sohler NL, et al. Home- versus office-based buprenorphine inductions for opioid-dependent patients. J Subst Abuse Treat. 2010;38(2):153\u20139.","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"72_CR36","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jsat.2010.04.001","volume":"39","author":"SD Whitley","year":"2010","unstructured":"Whitley SD, et al. Factors associated with complicated buprenorphine inductions. J Subst Abuse Treat. 2010;39(1):51\u20137.","journal-title":"J Subst Abuse Treat"},{"issue":"4","key":"72_CR37","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1056\/NEJMoa055255","volume":"355","author":"DA Fiellin","year":"2006","unstructured":"Fiellin DA, et al. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med. 2006;355(4):365\u201374.","journal-title":"N Engl J Med"},{"issue":"2","key":"72_CR38","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0002-9343(98)00194-6","volume":"105","author":"PG O\u2019Connor","year":"1998","unstructured":"O\u2019Connor PG, et al. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. Am J Med. 1998;105(2):100\u20135.","journal-title":"Am J Med"},{"issue":"11","key":"72_CR39","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/j.1525-1497.2005.0228.x","volume":"20","author":"MD Stein","year":"2005","unstructured":"Stein MD, Cioe P, Friedmann PD. Buprenorphine retention in primary care. J Gen Intern Med. 2005;20(11):1038\u201341.","journal-title":"J Gen Intern Med"},{"issue":"4","key":"72_CR40","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/ADM.0b013e31829727b2","volume":"7","author":"CO Cunningham","year":"2013","unstructured":"Cunningham CO, et al. Prior buprenorphine experience is associated with office-based buprenorphine treatment outcomes. J Addict Med. 2013;7(4):287\u201393.","journal-title":"J Addict Med"},{"issue":"10","key":"72_CR41","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.addbeh.2014.05.007","volume":"39","author":"A Bukten","year":"2014","unstructured":"Bukten A, et al. Factors associated with dropout among patients in opioid maintenance treatment (OMT) and predictors of re-entry. A national registry-based study. Addict Behav. 2014;39(10):1504\u20139.","journal-title":"Addict Behav"},{"issue":"4","key":"72_CR42","doi-asserted-by":"crossref","first-page":"605","DOI":"10.15288\/jsad.2013.74.605","volume":"74","author":"JS Potter","year":"2013","unstructured":"Potter JS, et al. Buprenorphine\/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START). J Stud Alcohol Drugs. 2013;74(4):605\u201313.","journal-title":"J Stud Alcohol Drugs"},{"issue":"3","key":"72_CR43","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jsat.2014.04.006","volume":"47","author":"Z Schuman-Olivier","year":"2014","unstructured":"Schuman-Olivier Z, et al. Emerging adult age status predicts poor buprenorphine treatment retention. J Subst Abuse Treat. 2014;47(3):202\u201312.","journal-title":"J Subst Abuse Treat"},{"issue":"16","key":"72_CR44","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1001\/jama.2015.3474","volume":"313","author":"G D\u2019Onofrio","year":"2015","unstructured":"D\u2019Onofrio G, et al. Emergency department-initiated buprenorphine\/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015;313(16):1636\u201344.","journal-title":"JAMA"},{"issue":"1","key":"72_CR45","doi-asserted-by":"crossref","first-page":"74 e11","DOI":"10.1016\/j.amjmed.2012.07.005","volume":"126","author":"DA Fiellin","year":"2013","unstructured":"Fiellin DA, et al. A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine. Am J Med. 2013;126(1):74 e11\u20137.","journal-title":"Am J Med"},{"issue":"3","key":"72_CR46","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/ADM.0b013e3182596492","volume":"6","author":"BA Moore","year":"2012","unstructured":"Moore BA, et al. Counseling and directly observed medication for primary care buprenorphine maintenance: a pilot study. J Addict Med. 2012;6(3):205\u201311.","journal-title":"J Addict Med"},{"issue":"4","key":"72_CR47","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jsat.2012.07.011","volume":"43","author":"JM Tetrault","year":"2012","unstructured":"Tetrault JM, et al. Brief versus extended counseling along with buprenorphine\/naloxone for HIV-infected opioid dependent patients. J Subst Abuse Treat. 2012;43(4):433\u20139.","journal-title":"J Subst Abuse Treat"},{"issue":"12","key":"72_CR48","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1001\/archgenpsychiatry.2011.121","volume":"68","author":"RD Weiss","year":"2011","unstructured":"Weiss RD, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry. 2011;68(12):1238\u201346.","journal-title":"Arch Gen Psychiatry"},{"key":"72_CR49","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jsat.2015.05.005","volume":"57","author":"LB Monico","year":"2015","unstructured":"Monico LB, et al. Buprenorphine treatment and 12-step meeting attendance: conflicts, compatibilities, and patient outcomes. J Subst Abuse Treat. 2015;57:89\u201395.","journal-title":"J Subst Abuse Treat"},{"key":"72_CR50","first-page":"143","volume":"7","author":"P Polomeni","year":"2014","unstructured":"Polomeni P, Schwan R. Management of opioid addiction with buprenorphine: French history and current management. Int J Gen Med. 2014;7:143\u20138.","journal-title":"Int J Gen Med"}],"container-title":["Addiction Science & Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-017-0072-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T21:25:05Z","timestamp":1750022705000},"score":1,"resource":{"primary":{"URL":"http:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-017-0072-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,28]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["72"],"URL":"https:\/\/doi.org\/10.1186\/s13722-017-0072-2","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,28]]},"article-number":"7"}}